Infinity Pharmaceuticals, Inc., is a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer in multiple clinical studies.

Biotechnology

Pharmaceutical

Infinity Pharmaceuticals

Eva Huang

Idelfonso Méndez

Devon Jones

Heywood Ellenburg

Mohammed Nurullah

Saveria Cristiano

Joseph McPherson

Steve Cucinotta

Nora Zizlsperger

Somarajan Nair

Naglaa Fikry

Liya Megerssa

Jasim Uddin

Khaled Oukasha

Deirdre Casale

The Scientific and Clinical Advisory Team at Infinity Pharmaceuticals provides expert guidance on the development of eganelisib (IPI-549). This team of scientific and clinical advisors collaborates on research strategies, clinical study designs, and the interpretation of data to advance this immuno-oncology therapeutic for cancer treatment.

Scientific and Clinical Advisory Team

Project and Operations Management

Healthcare Team

��

Scientific and Clinical Advisory Team

About

Team members

Other teams at Infinity Pharmaceuticals

Project and Operations Management

Healthcare Team

��������

Scientific and Clinical Advisory Team

About

Team members

Other teams at Infinity Pharmaceuticals

Project and Operations Management

Healthcare Team

��